{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:16:18Z","timestamp":1793661378715,"version":"4.5.1"},"reference-count":52,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent studies suggest that thrombophilic abnormalities and the use of oral contraceptives (OCs) are the leading causes of cerebral vein thrombosis (CVT). The purpose of this study was to assess the association between CVT and thrombophilic states, OCs, and their interaction. For data sources, we used the MEDLINE, EMBASE, and Cochrane Library databases (January 1994 to March 2005), reference lists of retrieved articles, and contact with content experts. We selected studies comparing the prevalence of OC use and the prevalence of prothrombitic abnormalities in patients with CVT compared with healthy controls. Two reviewers independently selected studies and extracted study characteristics, quality, and outcomes. Odds ratios (ORs) were calculated for each trial and pooled using the Mantel-Haenszel method. Seventeen studies were included. There was an increased risk of CVT in patients using OCs (OR 5.59; 95% confidence interval [CI] 3.95 to 7.91; P &lt; .001), and in patients with factor V Leiden (OR 3.38; 95% CI 2.27 to 5.05; P &lt; .001), with mutation G20 210A of prothrombin (OR 9.27; 95% CI 5.85 to 14.67; P &lt; .001) and with hyperhomocysteinemia (OR 4.07; 95% CI 2.54 to 6.52; P &lt; .001). We concluded that OC users, and patients with factor V Leiden, the prothrombin G20 120A mutation, and hyperhomocysteinemia are at a significantly increased risk of CVT.<\/jats:p>","DOI":"10.1182\/blood-2005-09-3578","type":"journal-article","created":{"date-parts":[[2006,1,6]],"date-time":"2006-01-06T01:54:34Z","timestamp":1136512474000},"page":"2766-2773","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":218,"title":["Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis"],"prefix":"10.1182","volume":"107","author":[{"given":"Francesco","family":"Dentali","sequence":"first","affiliation":[{"name":"From the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; and the Department of Clinical Medicine, University of Insubria, Varese, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Crowther","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; and the Department of Clinical Medicine, University of Insubria, Varese, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Ageno","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; and the Department of Clinical Medicine, University of Insubria, Varese, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111817120815800_REF1","doi-asserted-by":"crossref","unstructured":"Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35: 664-670.","DOI":"10.1161\/01.STR.0000117571.76197.26"},{"key":"2019111817120815800_REF2","doi-asserted-by":"crossref","unstructured":"Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin. 1992;10: 87-111.","DOI":"10.1016\/S0733-8619(18)30235-4"},{"key":"2019111817120815800_REF3","doi-asserted-by":"crossref","unstructured":"Gates PC. Cerebral venous thrombosis: a retrospective review. Aust N Z J Med. 1986;16: 766-770.","DOI":"10.1111\/j.1445-5994.1986.tb00033a.x"},{"key":"2019111817120815800_REF4","doi-asserted-by":"crossref","unstructured":"De Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke. 1999;30: 484-488.","DOI":"10.1161\/01.STR.30.3.484"},{"key":"2019111817120815800_REF5","doi-asserted-by":"crossref","unstructured":"Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90: 1004-1008.","DOI":"10.1073\/pnas.90.3.1004"},{"key":"2019111817120815800_REF6","doi-asserted-by":"crossref","unstructured":"Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature.1994;369: 64-67.","DOI":"10.1038\/369064a0"},{"key":"2019111817120815800_REF7","doi-asserted-by":"crossref","unstructured":"Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3\u2032-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88: 3698-3703.","DOI":"10.1182\/blood.V88.10.3698.bloodjournal88103698"},{"key":"2019111817120815800_REF8","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med. 1999;130: 643-650.","DOI":"10.7326\/0003-4819-130-8-199904200-00004"},{"key":"2019111817120815800_","doi-asserted-by":"crossref","unstructured":"Salomon O, Steinberg DM, Zivelin A, et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol. 1999;19: 511-518.","DOI":"10.1161\/01.ATV.19.3.511"},{"key":"2019111817120815800_REF10","unstructured":"Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism\u2014pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost. 2001;86: 809-816."},{"key":"2019111817120815800_REF11","doi-asserted-by":"crossref","unstructured":"World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346: 1575-1582.","DOI":"10.1016\/S0140-6736(95)91926-0"},{"key":"2019111817120815800_REF12","doi-asserted-by":"crossref","unstructured":"Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344: 1453-1457.","DOI":"10.1016\/S0140-6736(94)90286-0"},{"key":"2019111817120815800_REF13","doi-asserted-by":"crossref","unstructured":"McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, Guyatt G, for Evidence-Based Medicine Teaching Tips Working Group. Tips for learners of evidence-based medicine, 3: measures of observer variability (kappa statistic). CMAJ. 2004;171: 1369-1373.","DOI":"10.1503\/cmaj.1031981"},{"key":"2019111817120815800_REF14","doi-asserted-by":"crossref","unstructured":"Maclure M, Willett WC. Misinterpretation and misuse of the kappa statistic. Am J Epidemiol. 1987;126: 161-169.","DOI":"10.1093\/aje\/126.2.161"},{"key":"2019111817120815800_REF15","doi-asserted-by":"crossref","unstructured":"Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283: 2008-2012.","DOI":"10.1001\/jama.283.15.2008"},{"key":"2019111817120815800_REF16","doi-asserted-by":"crossref","unstructured":"Hayden GF, Kramer MS, Horwitz RI. The casecontrol study: a practical review for the clinician. JAMA. 1982;247: 326-331.","DOI":"10.1001\/jama.1982.03320280046028"},{"key":"2019111817120815800_REF17","unstructured":"Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22: 719-748."},{"key":"2019111817120815800_REF18","doi-asserted-by":"crossref","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327: 557-560.","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2019111817120815800_REF19","doi-asserted-by":"crossref","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7: 177-188.","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"2019111817120815800_REF20","doi-asserted-by":"crossref","unstructured":"Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323: 101-105.","DOI":"10.1136\/bmj.323.7304.101"},{"key":"2019111817120815800_REF21","doi-asserted-by":"crossref","unstructured":"Cantu C, Alonso E, Jara A, et al. Hyperhomocysteinemia, low folate and vitamin B12 concentrations, and methylene tetrahydrofolate reductase mutation in cerebral venous thrombosis. Stroke. 2004;35: 1790-1794.","DOI":"10.1161\/01.STR.0000132570.24618.78"},{"key":"2019111817120815800_REF22","doi-asserted-by":"crossref","unstructured":"Ventura P, Cobelli M, Marietta M, Panini R, Rosa MC, Salvioli G. Hyperhomocysteinemia and other newly recognized inherited coagulation disorders (factor V Leiden and prothrombin gene mutation) in patients with idiopathic cerebral vein thrombosis. Cerebrovasc Dis. 2004;17: 153-159.","DOI":"10.1159\/000075784"},{"key":"2019111817120815800_REF23","doi-asserted-by":"crossref","unstructured":"Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci PM. Hyperhomocysteinemia in cerebral vein thrombosis. Blood. 2003;102: 1363-1366.","DOI":"10.1182\/blood-2003-02-0443"},{"key":"2019111817120815800_REF24","doi-asserted-by":"crossref","unstructured":"Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol. 2002;70: 126-132.","DOI":"10.1002\/ajh.10103"},{"key":"2019111817120815800_REF25","doi-asserted-by":"crossref","unstructured":"Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998;338: 1793-1797.","DOI":"10.1056\/NEJM199806183382502"},{"key":"2019111817120815800_REF26","doi-asserted-by":"crossref","unstructured":"Weih M, Vetter B, Ziemer S, et al. Increased rate of factor V Leiden mutation in patients with cerebral venous thrombosis. J Neurol. 1998;245: 149-152.","DOI":"10.1007\/s004150050195"},{"key":"2019111817120815800_REF27","doi-asserted-by":"crossref","unstructured":"Delport R, Ubbink JB, Vermaak WJ, Rossouw H, Becker PJ, Joubert J. Hyperhomocysteinaemia in black patients with cerebral thrombosis. QJM. 1997;90: 635-639.","DOI":"10.1093\/qjmed\/90.10.635"},{"key":"2019111817120815800_REF28","doi-asserted-by":"crossref","unstructured":"Martinelli I, Rosendaal FR, Vandenbroucke JP, Mannucci PM. Oral contraceptives are a risk factor for cerebral vein thrombosis. Thromb Haemost. 1996;76: 477-478.","DOI":"10.1055\/s-0038-1650604"},{"key":"2019111817120815800_REF29","doi-asserted-by":"crossref","unstructured":"Gadelha T, Andre C, Juca AA, Nucci M. Prothrombin 20210A and oral contraceptive use as risk factors for cerebral venous thrombosis. Cerebrovasc Dis. 2005;19: 49-52.","DOI":"10.1159\/000081911"},{"key":"2019111817120815800_REF30","doi-asserted-by":"crossref","unstructured":"Rodrigues CA, Rocha LK, Morelli VM, Franco RF, Lourenco DM. Prothrombin G20210A mutation, and not factor V Leiden mutation, is a risk factor for cerebral venous thrombosis in Brazilian patients. J Thromb Haemost. 2004;2: 1211-1212.","DOI":"10.1111\/j.1538-7836.2004.00785.x"},{"key":"2019111817120815800_REF31","doi-asserted-by":"crossref","unstructured":"Boncoraglio G, Carriero MR, Chiapparini L, et al. Hyperhomocysteinemia and other thrombophilic risk factors in 26 patients with cerebral venous thrombosis. Eur J Neurol. 2004;11: 405-409.","DOI":"10.1111\/j.1468-1331.2004.00802.x"},{"key":"2019111817120815800_REF32","unstructured":"Meng Q, Pu C. [Cerebral venous thrombosis and factor V Leiden mutation.] Zhonghua Yi Xue Za Zhi. 2002;82: 47-49."},{"key":"2019111817120815800_REF33","doi-asserted-by":"crossref","unstructured":"Marietta M, Bertesi M, Simoni L, Castelli I, Cappi C, Torelli G. Cerebral vein thrombosis and lupus anticoagulant antibodies. Clin Appl Thromb Hemost. 2001;7: 238.","DOI":"10.1177\/107602960100700311"},{"key":"2019111817120815800_REF34","doi-asserted-by":"crossref","unstructured":"Madonna P, De Stefano V, Coppola A, Albisinni R, Cerbone AM. G20210A PRTH gene mutation and other thrombophilic polymorphisms in patients with cerebral vein thrombosis. Stroke. 2000;31: 1787-1788.","DOI":"10.1161\/01.STR.31.7.1785-c"},{"key":"2019111817120815800_REF35","doi-asserted-by":"crossref","unstructured":"Voetsch B, Damasceno BP, Camargo EC, et al. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost. 2000;83: 229-233.","DOI":"10.1055\/s-0037-1613791"},{"key":"2019111817120815800_REF36","doi-asserted-by":"crossref","unstructured":"Weih M, Vetter B, Castell S, Ziemer S, Kulozik AE, Einhaupl KM. Hereditary thrombophilia in cerebral venous thrombosis. Cerebrovasc Dis. 2000;10: 161-162.","DOI":"10.1159\/000016049"},{"key":"2019111817120815800_REF37","doi-asserted-by":"crossref","unstructured":"Christopher R, Nagaraja D, Dixit NS, Narayanan CP. Anticardiolipin antibodies: a study in cerebral venous thrombosis. Acta Neurol Scand. 1999;99: 121-124.","DOI":"10.1111\/j.1600-0404.1999.tb00669.x"},{"key":"2019111817120815800_REF38","doi-asserted-by":"crossref","unstructured":"Ludemann P, Nabavi DG, Junker R, et al. Factor V Leiden mutation is a risk factor for cerebral venous thrombosis: a case-control study of 55 patients. Stroke. 1998;29: 2507-2510.","DOI":"10.1161\/01.STR.29.12.2507"},{"key":"2019111817120815800_REF39","doi-asserted-by":"crossref","unstructured":"Reuner KH, Ruf A, Grau A, et al. Prothrombin gene G20210\u2014A transition is a risk factor for cerebral venous thrombosis. Stroke. 1998;29: 1765-1769.","DOI":"10.1161\/01.STR.29.9.1765"},{"key":"2019111817120815800_REF40","doi-asserted-by":"crossref","unstructured":"de Bruijn SF, Stam J, Vandenbroucke JP. Increased risk of cerebral venous sinus thrombosis with third-generation oral contraceptives. Cerebral Venous Sinus Thrombosis Study Group. Lancet. 1998;351: 1404.","DOI":"10.1016\/S0140-6736(05)79442-3"},{"key":"2019111817120815800_REF41","doi-asserted-by":"crossref","unstructured":"de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. The Cerebral Venous Sinus Thrombosis Study Group. BMJ. 1998;316: 589-592.","DOI":"10.1136\/bmj.316.7131.589"},{"key":"2019111817120815800_REF42","doi-asserted-by":"crossref","unstructured":"Scoditti U, Buccino GP, Pini M, Pattacini C, Mancia D. Risk of acute cerebrovascular events related to low oestrogen oral contraceptive treatment. Ital J Neurol Sci. 1998;19: 15-19.","DOI":"10.1007\/BF03028806"},{"key":"2019111817120815800_REF43","doi-asserted-by":"crossref","unstructured":"Zuber M, Toulon P, Marnet L, Mas JL. Factor V Leiden mutation in cerebral venous thrombosis. Stroke. 1996;27: 1721-1723.","DOI":"10.1161\/01.STR.27.10.1721"},{"key":"2019111817120815800_REF44","doi-asserted-by":"crossref","unstructured":"Kimber TE, Lloyd JV, Brophy BP, Thompson PD. Cerebral venous sinus thrombosis associated with factor V gene mutation. J Neurol Neurosurg Psychiatry. 1996;61: 204-205.","DOI":"10.1136\/jnnp.61.2.204"},{"key":"2019111817120815800_REF45","doi-asserted-by":"crossref","unstructured":"Martinelli I, Landi G, Merati G, Cella R, Tosetto A, Mannucci PM. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost. 1996;75: 393-394.","DOI":"10.1055\/s-0038-1650284"},{"key":"2019111817120815800_REF46","unstructured":"Margaglione M, Brancaccio V, Ciampa A, Papa ML, Grandone E, Di Minno G. Inherited thrombophilic risk factors in a large cohort of individuals referred to Italian thrombophilia centers: distinct roles in different clinical settings. Haematologica. 2001;86: 634-639."},{"key":"2019111817120815800_REF47","doi-asserted-by":"crossref","unstructured":"Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346: 1133-1134.","DOI":"10.1016\/S0140-6736(95)91803-5"},{"key":"2019111817120815800_REF48","doi-asserted-by":"crossref","unstructured":"Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med. 1997;127: 895-903.","DOI":"10.7326\/0003-4819-127-10-199711150-00007"},{"key":"2019111817120815800_","doi-asserted-by":"crossref","unstructured":"Den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 1998;80: 874-847.","DOI":"10.1055\/s-0037-1615380"},{"key":"2019111817120815800_REF50","doi-asserted-by":"crossref","unstructured":"College of American Pathologists Consensus Conference XXXVI: diagnostic issues in thrombophilia. Arch Pathol Lab Med. 2002;126: 1277-1433.","DOI":"10.5858\/2002-126-1277-COAPCC"},{"key":"2019111817120815800_REF51","doi-asserted-by":"crossref","unstructured":"Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344: 1222-1231.","DOI":"10.1056\/NEJM200104193441607"},{"key":"2019111817120815800_REF52","doi-asserted-by":"crossref","unstructured":"Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ. 2000;320: 1574-1577.","DOI":"10.1136\/bmj.320.7249.1574"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/7\/2766\/1338596\/zh800706002766.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/7\/2766\/1338596\/zh800706002766.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T08:28:11Z","timestamp":1626942491000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/7\/2766\/132046\/Thrombophilic-abnormalities-oral-contraceptives"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,1]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,4,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-09-3578","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,1]]}}}